Upadacitinib and its role in the treatment of vitiligo: A new possible therapeutic perspective

Abstract

Vitiligo, a chronic skin disorder characterized by the loss of melanocytes, affects approximately 0.5% to 2% of the global population.1 Despite its prevalence, the pathogenesis of vitiligo remains not completely understood. It is believed to be a complex disease involving genetic predisposition, environmental triggers, and autoinflammatory responses leading to melanocyte destruction.2 The management of vitiligo has been a challenge because of the unpredictable course of the disease and the variable response to treatment.

Topics & Concepts